LATAM Gaucher Disease Treatment Market Size, Share, Trends, & Industry Analysis Report By Type (Type 1, Type 3, and Type 2), By Therapy, By Distribution Channel, By Country – Market Forecast, 2025–2034

The LATAM Gaucher disease treatment market size is expected to reach USD 237.30 million by 2034, according to a new study by Polaris Market Research. The report “LATAM Gaucher Disease Treatment Market Size, Share, Trends, Industry Analysis Report By Type (Type 1, Type 3, and Type 2), By Therapy, By Distribution Channel, and By Country – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gaucher disease is a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase, leading to the accumulation of glucocerebroside in cells, particularly in the spleen, liver, bone marrow, and sometimes the brain.

Latin American governments are introducing health policies aimed at supporting rare disease patients, including those with Gaucher disease. Some countries have started creating national rare disease registries and policies that prioritize access to life-saving medications. Financial assistance programs and public-private partnerships are helping reduce the cost of expensive treatments, including enzyme replacement therapy. Additionally, health authorities are beginning to recognize Gaucher disease as a public health issue, which leads to increased funding for research, awareness, and treatment access. These supportive measures are helping more patients receive proper care and are driving demand for the treatment across Latin America.

Latin American countries are investing in their healthcare systems, improving access to advanced diagnostics and specialized treatments. New hospitals, labs, and clinics are being built or modernized, allowing for better patient care. More facilities now offer genetic testing and rare disease management, which helps detect Gaucher disease early. Governments and private organizations are further introducing more efficient drug distribution systems. These improvements make it easier for patients to get the medication they need. Better infrastructure supports diagnosis and treatment and boosts confidence in the healthcare system, thereby driving the market growth.

LATAM Gaucher Disease Treatment Market Report Highlights

By type, the type 2 segment accounted for USD 3.92 million in 2024. Type 2 Gaucher disease is a rare and severe form that affects infants and leads to serious neurological problems.

The substrate reduction therapy segment, based on therapy, accounted for a 26.98% share in 2024. SRT is an oral treatment option for Gaucher disease, offering an alternative to enzyme replacement therapy, especially for patients who cannot tolerate ERT.

The Brazil Gaucher disease treatment market accounted for a 42.72% market share in 2024, due to a well-established public healthcare system (SUS) that provides access to free enzyme replacement therapy for diagnosed patients.

The Mexico Gaucher disease treatment market is expected to reach USD 48.29 million by 2034, as awareness and healthcare access are improving across the country.

A few key market players in LATAM are Amicus Therapeutics, Inc.; CANbridge Life Sciences Ltd.; Eli Lilly and Company; Johnson & Johnson, Inc.; Lingyi Biotechnology; Protalix Biotherapeutics Inc.; Sanofi; Spur Therapeutics; Takeda Pharmaceutical; and ISU Abxis.

Polaris Market Research has segmented the LATAM Gaucher disease treatment market report on the basis of type, therapy, distribution channel, and region:

By Type (Revenue – USD Million, 2020–2034)

Type 1

Type 3

Type 2

By Therapy (Revenue – USD Million, 2020–2034)

Enzyme Replacement Therapy (ERT)

Substrate Reduction Therapy (SRT)

Others

By Distribution Channel (Revenue – USD Million, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Country Outlook (Revenue – USD Million, 2020–2034)

Brazil

Mexico

Argentina

Colombia

Chile

Peru

Ecuador

Paraguay

Rest of LATAM